Topic: Tibotec Pharmaceuticals Ltd.
Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected ...
NEW DELHI (Reuters) - India's rejection of patent applications on two life-saving HIV/AIDS drugs last week has been welcomed by health officials, who say it will ensure wider access to the medicines.India has the world's third highest caseload, with 2.5 million infections, ...
J and FDA issue warning to doctors about reports of dangerous skin reactions with HIV drugJohnson & Johnson has warned doctors about reports of potentially deadly allergic reactions in patients taking its HIV drug Intelence.J& J's Tibotec unit issued a letter to ...
Ninety-six week efficacy and safety data presented at ICAAC - . In Canada PREZISTA is marketed by Tibotec, a division of Janssen-Ortho Inc.. ARTEMIS is a 192-week study comparing the efficacy and safety of the protease inhibitors (PIs) PREZISTA/r and lopinavir/r in ...
